Company Directory - Research & Development
▼
- Choose category
- Clinical Research
- Devices
- Diagnostics
- Events
- Generics
- Government / Organisation
- Healthcare
- Manufacturing
- MedComms
- Other
- Pharmaco
- Pharmacy
- Publication / Journal
- Recruitment
- Research & Development
- Services
- Training
The Clinical & Contract Research Association (CCRA) is the voice for all organisations which provide clinical and contract development services for the pharmaceutical and biotechnology industries.
The Institute of Clinical Research (ICR) is the probably the oldest independent membership-led professional body for global clinical researchers.
For over 40 years, The Institute of Clinical Research (ICR) has provided high quality training, networking and support to the clinical research community. For many Members the Institute has been part of their life throughout their working careers, many have been with the Institute since its first incarnation as the ACRPI.
It is the membership that makes the Institute.
Kuros Biosciences is a leader in next generation synthetic bone graft technologies for targeted and controlled bone healing. Kuros’s bone graft substitute, MagnetOs, is commercialized in the US and UK for use in posterolateral spinal fusions. Kuros’s lead product in development, Fibrin PTH, a drug-biologic combination for spinal interbody fusion, has entered a phase 2 clinical trial in the U.S.
3B Pharmaceuticals GmbH (3BP) is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3BP has built a technology platform extending from hit identification to early clinical development.
4DMT is a gene therapy company with a transformative discovery platform—Therapeutic Vector Evolution—that enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease.
ADMA Biologics is an end-to-end biopharmaceutical company with three FDA-licensed approved products including ASCENIV™ (Immune Globulin Intravenous - slra, Human), BIVIGAM® (Immune Globulin Intravenous, Human), and NABI-HB® (hepatitis B immune globulin, human).
AMAL Therapeutics (AMAL) is a biotech, developing unique therapeutic vaccines and a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies. Our aim is to overcome the challenges around effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
Abzena is a life sciences group with its headquarters in San Diego, California with other sites across the US and Europe. Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry.
We are focused on leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people impacted by under served immuno-inflammatory conditions. Our team of experienced and accomplished kinome experts use the proprietary KINect® technology platform to generate clinical candidates for difficult to drug kinases with novel approaches.
We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
Adagene is a Nasdaq listed, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer. Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients.
Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies.
